MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Monopar Therapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$71.47+2.20 (+3.18%)
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –
Monopar Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Market Cap | $479.72M | $166.30M |
| Enterprise Value | $374.35M | $88.19M |
| PB Ratio | 3.67 | 2.03 |
| P/TBV Ratio | 3.67 | 2.29 |
Income (trailing twelve months)
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$22.12M | -$21.40M |
| Net Income | -$17.84M | -$22.46M |
| EBITDA | -$22.12M | -$16.91M |
| EPS (Diluted) | -$2.17 | -$0.83 |
Returns
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -19.5% | -53.2% |
| Return on Assets (ROA) | -18.9% | -40.9% |
| Return on Capital Employed (ROCE) | -16.9% | -38.1% |
Balance sheet
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $105.37M | $61.43M |
| Net Cash (Debt) | $105.37M | $15.35M |
| Net Cash Per Share | $15.70 | $0.66 |
| Equity (Book Value) | $130.86M | $49.09M |
| Book Value Per Share | $19.50 | $1.37 |
| Tangible Book Value | $130.86M | $23.52M |
| Working Capital | $130.75M | $76.81M |
Financial position
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 33.56 | 3.34 |
| Quick Ratio | 26.24 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$12.18M | -$12.35M |
Efficiency
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$811.13K | -$703.34K |
| Employee Count | 22 | 74 |
Dividends and yields
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.72% | -23.3% |
Shares
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 6,712,170 | 58,127,000 |
| Shares Change (YoY) | 46.1% | 10.9% |
| Shares Change (QoQ) | 0.20% | 0.54% |
| Shares Held by Institutions | 92.7% | 59.4% |
Scores
| Measure | Monopar Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 69.39 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Monopar Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.